What looked like a two-horse hepatitis C race between Gilead Sciences (NASDAQ: GILD ) and AbbVie (NYSE: ABBV ) has gotten more interesting, with Merck (NYSE: MRK ) and Bristol-Myers Squibb (NYSE: BMY ) presenting data on their hepatitis C drugs at a scientific meeting earlier this month.
While it's clear Gilead Sciences' Sovaldi combination product will be approved first, closely followed by AbbVie's combo drug, Merck's combination looks just as good and could be on the market in the not-to-distant future if the phase 3 data is as good as the recently presented phase 2 data.
Bristol-Myers Squibb's daclatasvir and asunaprevir are currently under review at the FDA. The pharma is applying for individual approval of the drugs, so daclatasvir -- arguably the more valuable of the two -- could be used in combination with Gilead's Sovaldi, much like Johnson & Johnson's (NYSE: JNJ ) Olysio is being used right now.
In the video below, senior biotech specialist Brian Orelli and health-care bureau chief Max Macaluso discus the ever-changing state of the hepatitis C space.
The hepatitis C market is huge, but not as big as this $14.4 trillion market
Let's face it, every investor wants to get in on revolutionary ideas before they hit it big. Like buying PC-maker Dell in the late 1980s, before the consumer computing boom. Or purchasing stock in e-commerce pioneer Amazon.com in the late 1990s, when it was nothing more than an upstart online bookstore. The problem is, most investors don't understand the key to investing in hyper-growth markets. The real trick is to find a small-cap "pure-play" and then watch as it grows in EXPLOSIVE lockstep with its industry. Our expert team of equity analysts has identified one stock that's poised to produce rocket-ship returns with the next $14.4 TRILLION industry. Click here to get the full story in this eye-opening report.